EXETEC 10 medium dogs

Main information

  • Trade name:
  • The Blue Cross Dog Wormer for Medium Dogs, Tablets
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • The Blue Cross Dog Wormer for Medium Dogs, Tablets
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • praziquantel, combinations
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0232/002
  • Authorization date:
  • 30-09-2011
  • EU code:
  • FR/V/0232/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

September2011

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

France EXETEC10

United-Kingdom TheBlueCross –DogWormerformediumdogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains

Activesubstances

Oxantel 200.28mg(equivalentto559mgofoxantelembonate)

Pyrantel 49.94mg(equivalentto144mgofpyrantelembonate)

Praziquantel 50.00mg

Excipienttoone950mgdivisibletablet

Excipients

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Tablet

Paleyellowtoyellow,oblongtabletwithbreakingline

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs

4.2 Indicationsforuse,specifyingthetargetspecies

Forcurativetreatmentofdogsharbouringmixedparasiticinfestationswiththefollowingadultstages

ofnematodeandcestodespecies:

Nematodes:

Toxocaracanis

Toxascarisleonina

Ancylostomacaninum

Uncinariastenocephala

Trichurisvulpis

Cestodes:

Dipylidiumcaninum

Taeniaspp

Echinococcusmultilocularis

Echinococcusgranulosus

4.3 Contraindications

Seesection4.8

4.4 Specialwarningsforeachtargetspecies

Parasiteresistancetoanyparticularclassofanthelminticmaydevelopfollowingfrequent,repeated

useofananthelminticofthatclass

Fleasserveasintermediatehostsforoneofthecommontapeworms –Dipylidiumcaninum.

Tapeworminfestationmayreoccurunlesscontrolofintermediatehosts(fleas)isundertaken.

September2011

4.5 Specialprecautionsforuse

i)Specialprecautionsforuseinanimals

RoundwormandHookworminfection:

Insomeanimals,AncylostomacaninumandToxocaracanismaynotbetotallyeradicatedbythe

treatment,resultinginacontinuedriskofeggsheddingintotheenvironment.Follow-upexaminations

ofthefaecesareadvisableandaccordingtotheresultsoftheseexaminations,treatmentwitha

nematodicidalproductmaybecarriedoutifnecessary.

Theproductisnotrecommendedforuseinpupsyoungerthantwomonthsoldorweighinglessthan

1kg.

Indebilitatedorheavilyinfestedanimals,theproductshouldbeusedonlyaccordingtoabenefit/risk

assessmentbytheresponsibleveterinarian

Donotuseinanimalswithknownhypersensitivitytoanyofthecomponentsoftheproduct.

ii)Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Someconstituentsofthisproductmaycauseallergicreactionsorskinirritation.

Avoidcontactwiththeskin.

Peoplewithknownhypersensitivitytoanyoftheingredientsshouldavoidcontactwiththisproduct.

Washhandsafteruse.

Incaseofaccidentalingestion,seekmedicaladviceandshowthepackageleaflettothephysician.

4.6 Adversereactions(frequencyandseriousness)

Vomitinganddiarrhoeamaybeobservedfollowingthetreatment.

Despitenotbeingobservedinstudiesperformedwiththeproduct,anorexiacanoccurasitisa

commonadverseeffectofproductscontainingpraziquantel.

4.7 Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduringpregnancyand

lactation.Theuseisnotrecommendedduringpregnancyandlactation.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Donotusesimultaneouslywithlevamisole,piperazineorcholineesteraseinhibitors

4.9 Amountstobeadministeredandadministrationroute

Therecommendeddoserateis20mgoxantel/5mgpyrantel/5mgpraziquantelperkgbodyweight,

ieonetabletper10kgbodyweightinasingleintake,byoralroute.

Administertherequirednumberoftablets,accordingtobodyweight,orally,inasingleadministration.

Preferably,dogsshouldbefastedpriortotreatment.Foodmaybegivenonehourormoreafter

treatment.

Weightofdog Numberoftablets

From3.1to5kg ½

From5.1to10kg 1

From10.1to20kg 2

From20.1to30kg 3

Thetabletcanbedividedintohalves.

Dogskepttogetherorinkennelsshouldbetreatedatthesametime.

4.10 Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Administrationoftheproducttohealthydogsat5timestherecommendeddosagefor6consecutive

weekshadnoadverseconsequences.

4.11 Withdrawalperiod(s)

Notapplicable.

September2011

5. PHARMACOLOGICALPROPERTIES

ATCvetCode:QP52AA51Praziquantel,combinations

5.1 Pharmacodynamicproperties

Theproductcontainsthreeactiveingredients,pyrantelembonate,oxantelembonateand

praziquantel.Thespectrumofactivityoftheproductiswide,directedtowardsgastro-intestinal

roundworms(ascaris,whipwormandhookworms)andtapeworms.

Pyrantelhasaparalysingeffectonroundwormmuscles,byactivatingacetylcholinereceptors.Its

activityismoreparticularlydirectedagainstToxocaracanis,Toxascarisleonina,Uncinaria

stenocephalaandAncylostomacaninum.ItsactivityagainstTrichurisvulpisisnegligible.

Oxantelisanm-oxyphenolicderivateofpyrantel,thathasbeendevelopedforitsactivityagainst

whipworms.

Praziquantelleadstomuscularcontractions,paralysisandalteredparasitetegumentintegrity.Itis

activeagainstadultsandlarvalstagesofdogtapeworms,Echinococcus,TaeniaandDipylidium.

5.2 Pharmacokineticparticulars

Afteroraladministration,theabsorptionofoxantelembonateisnegligible.Pyrantelisquickly

absorbedbutinsmallquantities(T

max =1.38h,C

=0.048µg/ml)andisveryquicklyeliminated.

Praziquantelisquicklyabsorbed(T

max =1.28h,C

=0.4µg/ml)andeliminated(eliminationhalf-life

1.5h).

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Dextrates

PovidoneK30

Sodiumlaurylsulphate

Baconflavour

Crospovidone

Sodiumstearylfumarate

6.2 Incompatibilities

Notapplicable

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:threeyears

Discardanyunusedhalftablet

6.4. Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

6.5 Natureandcompositionofimmediatepackaging

Polyamide-aluminium-PVC/aluminiumblisterorpolychlorotrifluoroethylene-PVC/aluminiumblister.

Cardboardboxwith1stripof3tablets

Cardboardboxwith6stripsof3tablets

Cardboardboxwith10stripsof3tablets

Cardboardboxwith20stripsof3tablets

Cardboardboxwith1stripof6tablets

Cardboardboxwith3stripsof6tablets

Cardboardboxwith5stripsof6tablets

Cardboardboxwith10stripsof6tablets

Notallpacksizesmaybemarketed

September2011

6.6 Special precautions for the disposal of unused veterinary medicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10 DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

September2011

OUTERPACKAGE

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

France EXETEC10

United-Kingdom TheBlueCross –DogWormerformediumdogs

2. STATEMENTOFACTIVEANDOTHERSUBSTANCES

Activesubstances

Oxantel 200.28mg(equivalentto559mgofoxantelembonate)

Pyrantel 49.94mg(equivalentto144mgofpyrantelembonate)

Praziquantel 50.00mg

Excipienttoone950mgdivisibletablet

3. PHARMACEUTICALFORM

Tablet

4. PACKAGESIZE

Cardboardboxwith1stripof3tablets

Cardboardboxwith6stripsof3tablets

Cardboardboxwith10stripsof3tablets

Cardboardboxwith20stripsof3tablets

Cardboardboxwith1stripof6tablets

Cardboardboxwith3stripsof6tablets

Cardboardboxwith5stripsof6tablets

Cardboardboxwith10stripsof6tablets

5. TARGETSPECIES

Dogs

6. INDICATIONS

Notincluded.

7. METHODANDROUTEOFADMINISTRATION

Oralroute.

Readthepackageleafletbeforeuse.

8. WITHDRAWALPERIOD

Notapplicable.

9. SPECIALWARNINGS,IFNECESSARY

Readthepackageleafletbeforeuse

10. EXPIRYDATE

EXP:

Discardanyunusedhalftablet

11. SPECIALSTORAGEPRECAUTIONS

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

12. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTSORWASTE

MATERIALS,IFANY

Askyourveterinarysurgeonhowtodisposeofmedicinesnolongerrequired.Thesemeasuresshould

helptoprotecttheenvironment.

September2011

13. THEWORDS“FORANIMALTREATMENTONLY”ANDCONDITIONSORRESTRICTIONS

REGARDINGSUPPLYANDUSE,ifapplicable

FORANIMALTREATMENTONLY

14. THEWORDS“KEEPOUTOFTHEREACHANDSIGHTOFCHILDREN”

Keepoutofthereachandsightofchildren.

15. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

16. MARKETINGAUTHORISATIONNUMBER(S)

17. MANUFACTURER’SBATCHNUMBER

Lot:

September2011

PACKAGELEAFLET

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDERANDOFTHE

MANUFACTURINGAUTHORISATIONHOLDERRESPONSIBLEFORBATCHRELEASE,IF

DIFFERENT

MarketingAuthorisationholder

Manufacturerforthebatchrelease:

VETOQUINOL

MAGNYVERNOIS

F-70200LURE

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

France EXETEC10

United-Kingdom TheBlueCross –DogWormerformediumdogs

3. STATEMENTOFACTIVEANDOTHERSUBSTANCES

Activesubstances

Oxantel 200.28mg(equivalentto559mgofoxantelembonate)

Pyrantel 49.94mg(equivalentto144mgofpyrantelembonate)

Praziquantel 50.00mg

Excipienttoone950mgdivisibletablet

4. INDICATIONS

Forcurativetreatmentofdogsharbouringmixedparasiticinfestationswiththefollowingadultstages

ofnematodeandcestodespecies:

Nematodes:

Toxocaracanis

Toxascarisleonina

Ancylostomacaninum

Uncinariastenocephala

Trichurisvulpis

Cestodes:

Dipylidiumcaninum

Taeniaspp

Echinococcusmultilocularis

Echinococcusgranulosus

5. CONTRAINDICATIONS

See paragraph“Specialwarnings”.

September2011

6. ADVERSEREACTIONS

Vomitinganddiarrhoeamaybeobservedfollowingthetreatment.

Despitenotbeingobservedinstudiesperformedwiththeproduct,anorexiacanoccurasitisa

commonadverseeffectofproductscontainingpraziquantel.

Ifyounoticeanyseriouseffectsorothereffectsnotmentionedinthisleaflet,pleaseinformyour

veterinarysurgeon.

7. TARGETSPECIES

Dogs.

8. DOSAGEFOREACHSPECIES,ROUTE(S)ANDMETHODOFADMINISTRATION

Therecommendeddoserateis20mgoxantel/5mgpyrantel/5mgpraziquantelperkgbodyweight,

ieonetabletper10kgbodyweightinasingleintake,byoralroute.

Administertherequirednumberoftablets,accordingtobodyweight,orally,inasingleadministration.

Preferably,dogsshouldbefastedpriortotreatment.Foodmaybegivenonehourormoreafter

treatment.

Weightofdog Numberoftablets

From3.1to5kg ½

From5.1to10kg 1

From10.1to20kg 2

From20.1to30kg 3

Thetabletcanbedividedintohalves.

Dogskepttogetherorinkennelsshouldbetreatedatthesametime.

9. ADVICEONCORRECTADMINISTRATION

None.

10. WITHDRAWALPERIOD

Notapplicable.

11. SPECIALSTORAGEPRECAUTIONS

Keepoutofthereachandsightofchildren.

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

DonotuseaftertheexpirydatewhichisstatedonthecartonafterEXP

Discardanyunusedhalftablet

12. SPECIALWARNINGS

Specialwarningsforeachtargetspecies

Parasiteresistancetoanyparticularclassofanthelminticmaydevelopfollowingfrequent,repeated

useofananthelminticofthatclass

Fleasserveasintermediatehostsforoneofthecommontapeworms –Dipylidiumcaninum.

Tapeworminfestationmayreoccurunlesscontrolofintermediatehosts(fleas)isundertaken.

September2011

Specialprecautionsforuseinanimals

RoundwormandHookworminfection:

Insomeanimals,AncylostomacaninumandToxocaracanismaynotbetotallyeradicatedbythe

treatment,resultinginacontinuedriskofeggsheddingintotheenvironment.Follow-upexaminations

ofthefaecesareadvisableandaccordingtotheresultsoftheseexaminations,treatmentwitha

nematodicidalproductmaybecarriedoutifnecessary.

Theproductisnotrecommendedforuseinpupsyoungerthantwomonthsoldorweighinglessthan

1kg.

Indebilitatedorheavilyinfestedanimals,theproductshouldbeusedonlyaccordingtoabenefit/risk

assessmentbytheresponsibleveterinarian

Donotuseinanimalswithknownhypersensitivitytoanyofthecomponentsoftheproduct.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinalproduct

toanimals

Someconstituentsofthisproductmaycauseallergicreactionsorskinirritation.

Avoidcontactwiththeskin.

Peoplewithknownhypersensitivitytoanyoftheingredientsshouldavoidcontactwiththisproduct.

Washhandsafteruse.

Incaseofaccidentalingestion,seekmedicaladviceandshowthepackageleaflettothephysician.

Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduringpregnancyand

lactation.Theuseisnotrecommendedduringpregnancyandlactation

Interactionwithothermedicinalproductsandotherformsofinteraction

Donotusesimultaneouslywithlevamisole,piperazineorcholineesteraseinhibitors

Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Administrationoftheproducttohealthydogsat5timestherecommendeddosagefor

6consecutiveweekshadnoadverseconsequences.

13. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTORWASTE

MATERIALS,IFANY

Askyourveterinarysurgeonhowtodisposeofmedicinesnolongerrequired.Thesemeasuresshould

helptoprotecttheenvironment.

14. DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

15. OTHERINFORMATION

Cardboardboxwith1stripof3tablets

Cardboardboxwith6stripsof3tablets

Cardboardboxwith10stripsof3tablets

Cardboardboxwith20stripsof3tablets

Cardboardboxwith1stripof6tablets

Cardboardboxwith3stripsof6tablets

Cardboardboxwith5stripsof6tablets

Cardboardboxwith10stripsof6tablets

Notallpacksizesmaybemarketed.

September2011

BLISTER

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

France EXETEC10

United-Kingdom TheBlueCross –DogWormerformediumdogs

2. NAMEOFTHEMARKETINGAUTHORISATIONHOLDER

3. EXPIRYDATE

EXP:

4. BATCHNUMBER

Lot:

5. THEWORDS“FORANIMALTREATMENTONLY”

Foranimaltreatmentonly.

13-12-2018

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

Published on: Wed, 12 Dec 2018 This report of the European Food Safety Authority and the European Centre for Disease Prevention and Control presents the results of zoonoses monitoring activities carried out in 2017 in 37 European countries (28 Member States (MS) and nine non-MS). Campylobacteriosis was the commonest reported zoonosis and its EU trend for confirmed human cases increasing since 2008 stabilised during 2013–2017. The decreasing EU trend for confirmed human salmonellosis cases since 2008 end...

Europe - EFSA - European Food Safety Authority Publications

30-11-2018

The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSEs) in 2017

The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSEs) in 2017

Published on: Thu, 29 Nov 2018 This report presents the results of surveillance on transmissible spongiform encephalopathies (TSEs) in bovine animals, sheep, goats, cervids and other animal species, as well as genotyping in sheep, carried out in 2017 in the European Union (EU) according to Regulation (EC) 999/2001, and in Iceland, Norway and Switzerland. In total, 1,312,714 cattle were tested by the 28 EU Member States (MSs) which is a decrease of 3% compared with 2016; 18,526 were tested by the three n...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Risk for animal and human health related to the presence of dioxins and dioxin-like PCBs in feed and food

Risk for animal and human health related to the presence of dioxins and dioxin-like PCBs in feed and food

Published on: Tue, 20 Nov 2018 The European Commission asked EFSA for a scientific opinion on the risks for animal and human health related to the presence of dioxins (PCDD/Fs) and DL‐PCBs in feed and food. The data from experimental animal and epidemiological studies were reviewed and it was decided to base the human risk assessment on effects observed in humans and to use animal data as supportive evidence. The critical effect was on semen quality, following pre‐ and postnatal exposure. The critical s...

Europe - EFSA - European Food Safety Authority Publications

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

29-8-2018

Review of the existing maximum residue levels for sintofen according to Article 12 of Regulation (EC) No 396/2005

Review of the existing maximum residue levels for sintofen according to Article 12 of Regulation (EC) No 396/2005

Published on: Tue, 28 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance sintofen. To assess the occurrence of sintofen residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Commission Regulation (EC) No 33/2008, as well as the European authorisations reported by Member ...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

30-4-2018

Stonewall Kitchen Voluntarily Recalls a Limited Amount of Basil Pesto Aioli due to Mislabeling and Undeclared Presence of the Dairy Allergen, Egg

Stonewall Kitchen Voluntarily Recalls a Limited Amount of Basil Pesto Aioli due to Mislabeling and Undeclared Presence of the Dairy Allergen, Egg

Stonewall Kitchen is voluntarily recalling a limited amount of 10.25oz Basil Pesto Aioli with an Enjoy By date of 28 Sep 2019 which may contain the undeclared allergen egg, as we may have inadvertently placed the label for our Basil Pesto on a small portion of our most recent production run.

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

10-8-2018

Sivextro (Merck Sharp and Dohme B.V.)

Sivextro (Merck Sharp and Dohme B.V.)

Sivextro (Active substance: tedizolid phosphate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5522 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2846/T/28

Europe -DG Health and Food Safety

28-3-2018

EU/3/04/241 (Roche Registration GmbH)

EU/3/04/241 (Roche Registration GmbH)

EU/3/04/241 (Active substance: Pirfenidone) - Transfer of orphan designation - Commission Decision (2018)2006 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/OD/052/04/T/03

Europe -DG Health and Food Safety

28-3-2018

EU/3/12/1092 (Astellas Pharma Europe B.V.)

EU/3/12/1092 (Astellas Pharma Europe B.V.)

EU/3/12/1092 (Active substance: Chimeric monoclonal antibody against claudin 6) - Transfer of orphan designation - Commission Decision (2018)2009 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/147/12/T/01

Europe -DG Health and Food Safety

28-3-2018

EU/3/10/803 (Astellas Pharma Europe B.V.)

EU/3/10/803 (Astellas Pharma Europe B.V.)

EU/3/10/803 (Active substance: Chimeric monoclonal antibody against claudin-18 splice variant 2) - Transfer of orphan designation - Commission Decision (2018)2007 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/083/10/T/01

Europe -DG Health and Food Safety